Core Viewpoint - The company announced a proposed 2025 Share Plan aimed at attracting and retaining key contributors to its long-term development and success, pending shareholder approval [1] Group 1 - The 2025 Share Plan is designed to recognize and reward participants for their past contributions to the company [1] - The plan will provide participants with opportunities to acquire proprietary rights of the company, encouraging further contributions to enhance the company's value [1] - The 2025 Share Plan offers a flexible approach for the company to retain, motivate, reward, and compensate participants, as well as provide benefits to them [1]

Group 1 - The core point of the article is that Enbio-B (09606.HK) announced a proposal for a share plan to be adopted on December 13, 2025, pending approval from the company's shareholders [1] Group 2 - The board of directors has made a recommendation regarding the share plan [1] - The implementation of the share plan is contingent upon shareholder approval [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不對因本通告全部或任何部份內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 普通決議案 考慮並酌情通過以下決議案為普通決議案： – 1 – 1. 「動議： (a) 待香港聯合交易所有限公司（「聯交所」）上市委員會批准根據2025年 股份計劃（其規則載於提交股東特別大會並由股東特別大會主席草簽 以資識別的標有「A」的文件）（「2025年股份計劃」）可能授出的獎勵 （「獎勵」）歸屬而可能須予配發及發行的股份上市及買賣後，茲批准 及採納2025年股份計劃，並授權董事及其授權代表為全面實施2025 年股份計劃而採取一切必要或適當的行動及訂立一切必要或適當的交 易、安排及協議，包括但不限於： (i) 管理2025年股份計劃； (ii) 不時修改及╱或修訂2025年股份計劃，惟有關修改及╱或修訂 須根據2025年股份計劃有關修改及╱或修訂的條文進行，並須 遵守上市規則第17章； Duality Biotherapeutics, Inc. 映恩生物 （於開曼群島註冊成立的有限公司） （股份代號 ...

此乃要件 請即處理 映恩生物 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交易商、 銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下之映恩生物股份全部售出或轉讓，應立即將本通函及代表委任表格送交買主或承讓人或送 交經手買賣或轉讓之銀行、股票經紀或其他代理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因依賴該等內容而引致之任何 損失承擔任何責任。 Duality Biotherapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：9606） (1) 建議採納2025年股份計劃；及 (2) 股東特別大會通告 本公司謹訂於2025年12月30日（星期二）上午九時正假座中國上海市浦東新區櫻花路868號A座11樓董 事會會議室舉行股東特別大會（「股東特別大會」），大會通告載於本通函第EGM-1至EGM-3頁。股東 特別大會適用的代表委任表格刊載於香港聯合交易所有限公司網站( www.hkexnews.hk ) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 Duality Biotherapeutics, Inc. 映恩生物 （根據開曼群島法律註冊成立的有限公司） （股份代號：9606） 建議採納2025年股份計劃 建議採納2025年股份計劃 於2025年12月13日，映恩生物（「本公司」，連同其附屬公司統稱「本集團」）之董 事（「董事」）會（「董事會）議決建議採納2025年股份計劃，惟須經本公司股東（「股 東」）批准方可作實。 2025年股份計劃旨在吸引及挽留對本集團長期發展及成功作出重要貢獻的參與人 士（「參與人士」），表彰並獎勵參與人士過去對本集團的貢獻，為參與人士提供收 購本公司專有權益的機會，並鼓勵參與人士進一步為本公司作出貢獻，致力提升 本公司及其股份（「股份」）的價值，從而造福本公司及其全體股東。2025年股份計 劃將為本公司提供靈活的方式，以挽留、激勵、獎勵、酬勞、補償參與人士及╱ 或為彼等提供福利。 2025年股份計劃將構成香港聯合交易所有限 ...

Group 1 - The Hong Kong innovative drug sector is experiencing a rebound, with the Hang Seng Innovative Drug Index rising by 1.3%, potentially ending a four-day decline [1] - Notable stocks in the sector include Kangfang Biotech, which rose over 5%, and other companies like Yimeng Biotech, Cloudtop, and Nuocheng Jianhua, which saw increases of over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 500 million yuan, indicating strong investor interest [1] Group 2 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the implementation of a new "medical insurance directory" and "commercial insurance innovative drug directory" starting January 1, 2026 [1] - The medical insurance directory will add 114 new drugs, including 50 first-class innovative drugs, while the first version of the commercial insurance directory will include 19 drugs, marking a significant advancement in the multi-layered medical insurance system [1] - According to a report by Zhongtai Securities, innovative drugs remain the most important theme in the pharmaceutical sector, with recent price adjustments leading to a more reasonable valuation and increased investment safety margins and return potential [1] Group 3 - The Hang Seng Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drug companies in Hong Kong, and the Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index [1] - This ETF provides investors with a convenient way to capitalize on investment opportunities within the innovative drug sector [1]

Group 1 - The core viewpoint of the report highlights that the pharmaceutical industry in China is experiencing a reversal in 2025, driven by innovative drugs, with significant benefits observed in the CXO and upstream supply chain sectors, particularly in the Hong Kong stock market where innovative drugs have seen a rise of over 80% year-to-date [1][4] - The report emphasizes that the core catalyst for innovative drugs comes from policy support and the realization of business development (BD) opportunities abroad, with notable transactions exceeding 1 billion USD, validating the international competitiveness of Chinese innovative drugs [1][2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, allowing for the inclusion of high-value innovative drugs in commercial insurance, addressing the gap in coverage for expensive treatments [1][2] Group 2 - The report indicates a rapid growth trend in the number of license-out transactions by Chinese pharmaceutical companies, with total upfront payments reaching 6.298 billion USD, a 53% year-on-year increase, and total transaction amounts reaching 118.862 billion USD, a 125% increase [2] - Looking ahead to 2026, the report suggests a shift from "BD-driven" to "data-driven" investment in innovative drugs, emphasizing the importance of clinical data validation and commercial capabilities for revenue growth [2] - Recommended stocks for investment include Heng Rui Medicine, Kelun-Biotech, and Teva Biopharmaceuticals, among others, while companies like Kangfang Biotech and Innovent Biologics are suggested for further attention [2][3] Group 3 - The overall profitability of the pharmaceutical sector remains stable, with a gradual improvement in the profitability of the pharmaceutical manufacturing industry, despite a slight decline in revenue growth [11][15] - The report notes a significant divergence within the industry, with the medical services sector performing well, while the profits of the biopharmaceutical sector have seen a substantial decline [28][29] - The report highlights that the medical insurance fund's income and expenditure growth rates are stabilizing, indicating a long-term trend towards cost control in medical insurance, which is essential for the sustainable development of the innovative drug industry [31][36]

值得注意的是，深交所将迎来H股回A首家企业。港股龙头公司光大环境宣布启动"回A"计划，拟在深 交所上市。 今年11月14日，光大环境公告称，拟发行不超过8亿股A股，计划登陆深交所。这是中办、国办印发 《关于深入推进深圳综合改革试点深化改革创新扩大开放的意见》后，首家宣布回A的粤港澳大湾区港 股企业。 后续还有哪些港股公司回A？以深交所为例，按照深交所红筹企业回A条件，已在境外上市的红筹企业 在深市主板二次上市的标准为：市值不低于2000亿元；市值200亿元以上，拥有自主研发、国际领先技 术，科技创新能力较强，在同行业竞争中处于相对优势地位。 截至12月9日，在港交所上市且未在A股上市的粤港澳大湾区企业中，满足市值超过2000亿元的企业有3 家，分别为腾讯控股、港交所、腾讯音乐；而满足市值200亿元以上要求的企业逾20家，典型企业包括 小鹏汽车-W、华润电力、比亚迪电子、思摩尔国际、优必选、金蝶国际、晶泰控股、中国燃气、名创 优品、小马智行-W、高伟电子、华润饮料、文远知行-W等。 （原标题：H股回A迎来年内首家公司 百奥赛图今日登陆科创板，深交所也将迎来H股回A首家企业） H股回A迎来年内首家公司。百奥赛图1 ...

Core Insights - The core viewpoint emphasizes that Biotech will remain a mainstream investment direction in the medical field, particularly focusing on the iteration of second-generation technology paradigms, such as advancements in ADC drugs and CAR-T therapies [1][2]. Group 1: Investment Trends - There is a notable phenomenon of "asset grabbing" in the market, driven by the transition of innovative drug enthusiasm from the secondary market to the primary market [1]. - As of September this year, over 40% of the innovative assets introduced by the top 20 multinational pharmaceutical companies (MNCs) in China are from local biotech firms, with half of these being next-generation therapies like dual antibodies and ADCs [2]. - Biotech companies have secured 75% of external licensing transactions, with five companies, including Hengrui Medicine and Innovent Biologics, accounting for 20% of these deals [2]. Group 2: Challenges and Opportunities - Despite the growth, the industry faces multiple challenges, including the risk of resource wastage and product homogeneity due to blind competition [3]. - The focus should shift from speed to quality improvement and differentiated innovation to avoid collective setbacks in the industry [3]. - Building a bridge between technology development and clinical needs is crucial for efficient commercialization, as demonstrated by Sequoia China's efforts in the neuroscience field [3]. Group 3: BD Transactions and Value Creation - The core value of business development (BD) transactions lies in the synergy of capital, brand, and capability, which can provide stable cash flow and enhance brand credibility for biotech companies [4]. - High-quality BD collaborations can significantly aid biotech firms in learning from leading pharmaceutical companies, thus enhancing their operational capabilities [4]. - The perception that Chinese biotech assets are undervalued in international markets needs to be addressed to improve their global competitiveness [5]. Group 4: Strategic Investment Considerations - The essence of primary market investment is to buy today and realize returns in 5 to 10 years, necessitating a focus on long-term value rather than short-term market trends [6]. - Sequoia China emphasizes the importance of selecting the right direction and team when investing, as these factors are critical for maximizing value returns [6]. - The current market environment, including the opening of the Sci-Tech Innovation Board and the surge in biotech listings in Hong Kong, provides more financing opportunities for companies, but they must ensure their fundamentals are solid before going public [6].

Group 1 - The first H-share company to return to A-shares in 2023 is Bai Aosai Tu, which officially listed on the Sci-Tech Innovation Board on December 10, following its listing on the Hong Kong Stock Exchange in 2022 [1] - Bai Aosai Tu has a total share capital of 446.9 million shares, with 399.4 million shares being H-shares. The A-share issuance price is 26.68 yuan per share, and the total amount expected to be raised from the A-share IPO is 1.267 billion yuan [1] - Another Hong Kong company, Ying En Biology, has completed the listing guidance filing for the Sci-Tech Innovation Board and has officially started its return to A-share process [1] Group 2 - Everbright Environment, a leading Hong Kong company, has announced its plan to return to A-shares by issuing up to 800 million A-shares and plans to list on the Shenzhen Stock Exchange [2] - As of December 9, there are three companies listed on the Hong Kong Stock Exchange that meet the criteria of having a market capitalization exceeding 200 billion yuan, including Tencent Holdings, Hong Kong Stock Exchange, and Tencent Music [2] - More than 20 companies from the Guangdong-Hong Kong-Macao Greater Bay Area meet the requirement of having a market capitalization above 20 billion yuan, including notable firms like Xpeng Motors, China Resources Power, BYD Electronics, and others [2] Group 3 - The requirements for red-chip companies to list on the ChiNext board mainly target those not listed overseas, with standards including rapid revenue growth and expected market capitalization of no less than 10 billion yuan [3] - In Guangdong Province, nearly 50 red-chip companies have a market capitalization exceeding 10 billion yuan, while around 20 companies have a market capitalization between 5 billion and 10 billion yuan and are expected to have revenue exceeding 500 million yuan in 2024 [3] - Compared to the Shenzhen main board, there are more companies from the Greater Bay Area that meet the return criteria for the ChiNext board [3]